![conference banner](/images/conference-banner.jpeg)
Abstract
Today, we are experiencing a real cultural revolution in the therapeutic approach to cancer of the colon - rectum, that by orphan disease, it is now becoming an important paradigm of scientific innovations and concepts.
Survival of patients with metastatic colorectal cancer (m-CRC) has been significantly improved with the introduction of the monoclonal antibodies that have as target the vascular endothelial growth factor (VEGF) and the epidermal growth factor receptor (EGFR).
The PD-1/PD-L1 pathway in cancer is implicated in tumors escaping immune destruction. This pathway is up -regulated in many tumours. Blockade of this pathway with anti-PD-1 and anti-PD-L1 agents has led to remarkable clinical responses in patients affected by many different types of cancer.
The aim of this review is to evaluate the effects of addiction of biological agents to standard chemotherapy in the treatment of m-CRC.
We can say that, among the various treatment options, the challenge of the future will be a better selection of the population, to ensure the best possible benefit from treatment with anti-VEGF drugs or anti-EGFR and a careful and customized planning of the therapeutic strategy for each patient.
Keywords: Colorectal cancer, monoclonal antibodies, target therapy, treatment, anti-VEGF drugs, anti-EGFR.
Current Cancer Drug Targets
Title:Metastatic Colorectal Cancer: Role of Target Therapies and Future Perspectives
Volume: 18 Issue: 5
Author(s): Anna Nappi, Massimiliano Berretta, Carmela Romano, Salvatore Tafuto, Antonino Cassata, Rossana Casaretti, Lucrezia Silvestro, Chiara De Divitiis, Lara Alessandrini, Francesco Fiorica, Alessandro Ottaiano and Guglielmo Nasti*
Affiliation:
- Medical Oncology, Abdominal Department, National Cancer Institute G. Pascale Foundation, 80131 Napoli,Italy
Keywords: Colorectal cancer, monoclonal antibodies, target therapy, treatment, anti-VEGF drugs, anti-EGFR.
Abstract: Today, we are experiencing a real cultural revolution in the therapeutic approach to cancer of the colon - rectum, that by orphan disease, it is now becoming an important paradigm of scientific innovations and concepts.
Survival of patients with metastatic colorectal cancer (m-CRC) has been significantly improved with the introduction of the monoclonal antibodies that have as target the vascular endothelial growth factor (VEGF) and the epidermal growth factor receptor (EGFR).
The PD-1/PD-L1 pathway in cancer is implicated in tumors escaping immune destruction. This pathway is up -regulated in many tumours. Blockade of this pathway with anti-PD-1 and anti-PD-L1 agents has led to remarkable clinical responses in patients affected by many different types of cancer.
The aim of this review is to evaluate the effects of addiction of biological agents to standard chemotherapy in the treatment of m-CRC.
We can say that, among the various treatment options, the challenge of the future will be a better selection of the population, to ensure the best possible benefit from treatment with anti-VEGF drugs or anti-EGFR and a careful and customized planning of the therapeutic strategy for each patient.
Export Options
About this article
Cite this article as:
Nappi Anna, Berretta Massimiliano, Romano Carmela, Tafuto Salvatore, Cassata Antonino, Casaretti Rossana, Silvestro Lucrezia, Divitiis De Chiara, Alessandrini Lara, Fiorica Francesco, Ottaiano Alessandro and Nasti Guglielmo*, Metastatic Colorectal Cancer: Role of Target Therapies and Future Perspectives, Current Cancer Drug Targets 2018; 18 (5) . https://dx.doi.org/10.2174/1568009617666170209095143
DOI https://dx.doi.org/10.2174/1568009617666170209095143 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
Role of Immune and Genotoxic Response Biomarkers in Tumor Microenvironment in Cancer Diagnosis and Treatment
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process of exploring and investigating the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prognostic Value and Clinicopathological Differences of Bmi1 in Gastric Cancer: A Meta-analysis
Anti-Cancer Agents in Medicinal Chemistry Bridging ‘Green’ with Nanoparticles: Biosynthesis Approaches for Cancer Management and Targeting of Cancer Stem Cells
Current Nanoscience Fluoropyrimidine-associated Toxicities in Colorectal Cancer Patients: The Epigenetic Point of View
Clinical Cancer Drugs Chronic Inflammation and Cancer: The Role of Endothelial Dysfunction and Vascular Inflammation
Current Pharmaceutical Design Clinical and Translational Research Challenges in Biliary Tract Cancers
Current Medicinal Chemistry Possibility of Non-Immunosuppressive Immunophilin Ligands as Potential Therapeutic Agents for Parkinsons Disease
Current Pharmaceutical Design Electronic Noses in Medical Diagnostics
Current Medicinal Chemistry Pancreatic Cancer in Obesity: Epidemiology, Clinical Observations, and Basic Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Current Strategies for the Treatment of Ulcerative Colitis
Recent Patents on Inflammation & Allergy Drug Discovery Cadmium as an Endocrine Disruptor in the Reproductive System
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Kruppel-Like Factors 4 and 5: Unity in Diversity
Current Genomics MicroRNAs in Genetic Disease: Rethinking the Dosage
Current Gene Therapy The Role of Neuronal Pathways in Gastrointestinal Cancers: Targets for Prevention and Treatment
Letters in Drug Design & Discovery [1, 2, 4]-Oxadiazoles: Synthesis and Biological Applications
Mini-Reviews in Medicinal Chemistry Synthesis and Biological Evaluation of 1,5-Naphthyridines as Topoisomerase I Inhibitors. A New Family of Antiproliferative Agents
Current Topics in Medicinal Chemistry Combining Gene Therapy and Radiation Against Cancer
Current Gene Therapy Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity
Current Cancer Therapy Reviews Molecular and Cellular Mechanisms of Hexavalent Chromium-Induced Lung Cancer: An Updated Perspective
Current Drug Metabolism Alpha-MSH Targeted Liposomal Nanoparticle for Imaging in Inflammatory Bowel Disease (IBD)
Current Pharmaceutical Design The Role of Skin and Gut Microbiome and Epigenetic Modifications in Skin-Autoimmune Disorders
Current Molecular Medicine